{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:31:24Z","timestamp":1795033884504,"version":"4.10.2"},"reference-count":44,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>A dysfunctional immune tumor microenvironment facilitates disease progression in multiple myeloma (MM). Using multiplex immunohistochemistry (mIHC), we describe the quantitative and qualitative changes in CD3+CD8+ cytotoxic T cells and assess their proximity to malignant plasma cells (PC) in patients with monoclonal gammopathy of undetermined significance (MGUS), and newly diagnosed (ND) and relapsed and\/or refractory (RR) MM. Formalin-fixed, paraffin-embedded trephine sections from patients with MGUS (N=32), NDMM (N=65), and RRMM (N=59) were sequentially stained for CD138, CD3, CD8, and checkpoint receptors (CPR) Tim-3, Lag-3, and PD-1. The Halo\u00ae image analysis platform was used for cell segmentation and phenotyping, facilitating enumeration of cytotoxic T cells and analysis of proximity to PC. The percentage of CD8+ cytotoxic T cells in proximity to PC is greater in patients with NDMM than patients with RRMM (at 50 \u03bcm distance, 90.8% vs. 81.5%; P=0.038). There is a trend for more CD3+ T cells in MGUS (P=0.08) but no difference was observed in the prevalence of CD8+ cytotoxic T cells (P=0.48). Lag-3 is the most common CPR expressed on cytotoxic T cells in myeloma (P&lt;0.0001), while PD-1 is the most common CPR on CD8- T cells of patients with MGUS and RRMM. Our study is the first to report on the spatial relationship between T cells and PC using mIHC on FFPE bone marrow trephine sections from patients with PC dyscrasia. The proximity of T cells to PC during early stages of MM, and overexpression of Lag-3, validate the move of immune therapeutic strategies, including T-cell engagers and checkpoint inhibitors, to upfront treatment or in early-line treatment of MM.<\/jats:p>","DOI":"10.3324\/haematol.2023.283344","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:37:26Z","timestamp":1697686646000},"page":"1487-1500","source":"Crossref","is-referenced-by-count":7,"title":["Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients"],"prefix":"10.3324","volume":"109","author":[{"given":"Slavisa","family":"Ninkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise E.","family":"Purton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"60687","doi-asserted-by":"crossref","unstructured":"Cohen AD. Myeloma: next generation immunotherapy. Hematology. 2019; 2019(1):266-272.","DOI":"10.1182\/hematology.2019000068"},{"key":"60688","doi-asserted-by":"crossref","unstructured":"Ninkovic S, Quach H. Shaping the treatment paradigm based on the current understanding of the pathobiology of multiple myeloma: an overview. Cancers. Cancers (Basel). 2020; 12(11):3488.","DOI":"10.3390\/cancers12113488"},{"key":"60689","doi-asserted-by":"crossref","unstructured":"Soekojo CY, Ooi M, De Mel S, Chng WJ. Immunotherapy in multiple myeloma. Cells. 2020; 9(3):601.","DOI":"10.3390\/cells9030601"},{"key":"60690","doi-asserted-by":"crossref","unstructured":"Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapies. Blood Cancer J. 2015; 5(7):e306.","DOI":"10.1038\/bcj.2015.32"},{"key":"60691","doi-asserted-by":"crossref","unstructured":"Raitakari M, Brown RD, Sze D. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol. 2000; 110(1):203-209.","DOI":"10.1046\/j.1365-2141.2000.02131.x"},{"key":"60692","doi-asserted-by":"crossref","unstructured":"Pessoa De Magalhaes RJ, Vidriales M-B, Paiva B. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013; 98(1):79-86.","DOI":"10.3324\/haematol.2012.067272"},{"key":"60693","doi-asserted-by":"crossref","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016; 9(1):e321.","DOI":"10.1186\/s13045-016-0345-3"},{"key":"60694","doi-asserted-by":"crossref","unstructured":"Tan J, Chen S, Huang J. Increased exhausted CD8(+) T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma. Asia Pac J Clin Oncol. 2018; 14(5):e266-e274.","DOI":"10.1111\/ajco.13033"},{"key":"60695","doi-asserted-by":"crossref","unstructured":"Lucas F, Pennell M, Huang Y. T cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma. Biol Blood Marrow Transplant. 2020; 26(1):7-15.","DOI":"10.1016\/j.bbmt.2019.08.009"},{"key":"60696","doi-asserted-by":"crossref","unstructured":"Kwon M, Kim CG, Lee H. PD-1 Blockade reinvigorates bone marrow CD8(+) T cells from patients with multiple myeloma in the presence of TGF\u03b2 inhibitors. Clin Cancer Res. 2020; 26(7):1644-1655.","DOI":"10.1158\/1078-0432.CCR-19-0267"},{"key":"60697","doi-asserted-by":"crossref","unstructured":"Guillerey C, Harjunp\u00e4\u00e4 H, Carri\u00e9 N. TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood. 2018; 132(16):1689-1694.","DOI":"10.1182\/blood-2018-01-825265"},{"key":"60698","doi-asserted-by":"crossref","unstructured":"Batorov EV, Aristova TA, Sergeevicheva VV. Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients. Sci Rep. 2020; 10(1):20846.","DOI":"10.1038\/s41598-020-77941-y"},{"key":"60699","doi-asserted-by":"crossref","unstructured":"Kreiniz N, Eiza N, Tadmor T. The involvement of LAG3+ plasma cells in the development of multiple myeloma. Blood. 2022; 140(Suppl 1):7112-7113.","DOI":"10.1182\/blood-2022-160432"},{"key":"60700","doi-asserted-by":"crossref","unstructured":"Bae J, Accardi F, Hideshima T. Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022; 36(1):138-154.","DOI":"10.1038\/s41375-021-01301-6"},{"key":"60701","doi-asserted-by":"crossref","unstructured":"Minnie SA, Kuns RD, Gartlan KH. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018; 132(16):1675-1688.","DOI":"10.1182\/blood-2018-01-825240"},{"key":"60702","doi-asserted-by":"crossref","unstructured":"Mateos MV, Orlowski RZ, Ocio EM. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019; 186(5):e117-e121.","DOI":"10.1111\/bjh.15946"},{"key":"60703","doi-asserted-by":"crossref","unstructured":"Badros A, Hyjek E, Ma N. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Blood. 2017; 130(10):1189-1197.","DOI":"10.1182\/blood-2017-03-775122"},{"key":"60704","unstructured":"Mateos M-V, Blacklock H, Schjesvold F. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019; 6(9):e459-e469."},{"key":"60705","doi-asserted-by":"crossref","unstructured":"Gide TN, Silva IP, Quek C. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. OncoImmunology. 2020; 9(1):1659093.","DOI":"10.1080\/2162402X.2019.1659093"},{"key":"60706","doi-asserted-by":"crossref","unstructured":"Li F, Li C, Cai X. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine. 2021; 41:101134.","DOI":"10.1016\/j.eclinm.2021.101134"},{"key":"60707","doi-asserted-by":"crossref","unstructured":"Fu T, Dai L-J, Wu S-Y. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021; 14(1):98.","DOI":"10.1186\/s13045-021-01103-4"},{"key":"60708","doi-asserted-by":"crossref","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020; 1(5):493-506.","DOI":"10.1038\/s43018-020-0053-3"},{"key":"60709","doi-asserted-by":"crossref","unstructured":"Wang J, Hu Y, Hamidi H. Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling. Front Oncol. 2022; 12:948548.","DOI":"10.3389\/fonc.2022.948548"},{"key":"60710","doi-asserted-by":"crossref","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022; 3(6):490-501.","DOI":"10.1158\/2643-3230.BCD-22-0018"},{"key":"60711","doi-asserted-by":"crossref","unstructured":"Bird J, Behrens J, Westin J. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009; 147(1):22-42.","DOI":"10.1111\/j.1365-2141.2009.07807.x"},{"key":"60712","doi-asserted-by":"crossref","unstructured":"Walters DK, Jelinek DF. Multiplex immunofluorescence of bone marrow core biopsies: visualizing the bone marrow immune contexture. J Histochem Cytochem. 2020; 68(2):99-112.","DOI":"10.1369\/0022155419896802"},{"key":"60713","unstructured":"Ng AP, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica. 2006; 91(7):972-975."},{"key":"60714","doi-asserted-by":"crossref","unstructured":"Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol. 2008; 61(2):213-216.","DOI":"10.1136\/jcp.2007.049130"},{"key":"60715","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-e548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"60716","doi-asserted-by":"crossref","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phaseselimination, equilibrium and escape. Curr Opin Immunol. 2014; 27:16-25.","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"60717","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Andres M, Almeida J, Martin-Ayuso M. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic\/Th1 T cells demonstrating a squed TCR-V\u03b2 repertoire. Cancer. 2006; 106(6):1296-1305.","DOI":"10.1002\/cncr.21746"},{"key":"60718","doi-asserted-by":"crossref","unstructured":"Camisaschi C, Casati C, Rini F. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol. 2010; 184(11):6545-6551.","DOI":"10.4049\/jimmunol.0903879"},{"key":"60719","doi-asserted-by":"crossref","unstructured":"Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019; 42:101305.","DOI":"10.1016\/j.smim.2019.101305"},{"key":"60720","doi-asserted-by":"crossref","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020; 20(3):173-185.","DOI":"10.1038\/s41577-019-0224-6"},{"key":"60721","doi-asserted-by":"crossref","unstructured":"Chung DJ, Pronschinske KB, Shyer JA. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016; 4(1):61-71.","DOI":"10.1158\/2326-6066.CIR-15-0055"},{"key":"60722","doi-asserted-by":"crossref","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017; 276(1):80-96.","DOI":"10.1111\/imr.12519"},{"key":"60723","doi-asserted-by":"crossref","unstructured":"Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol. 2020; 13(1):111.","DOI":"10.1186\/s13045-020-00947-6"},{"key":"60724","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022; 386(1):24-34.","DOI":"10.1056\/NEJMoa2109970"},{"key":"60725","doi-asserted-by":"crossref","unstructured":"Bryant C, Suen H, Brown R. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance. Blood Cancer J. 2013; 3(9):e148.","DOI":"10.1038\/bcj.2013.34"},{"key":"60726","doi-asserted-by":"crossref","unstructured":"Favaloro J, Brown R, Aklilu E. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma. 2014; 55(5):1090-1098.","DOI":"10.3109\/10428194.2013.825905"},{"key":"60727","doi-asserted-by":"crossref","unstructured":"Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003; 198(11):1753-1757.","DOI":"10.1084\/jem.20031030"},{"key":"60728","unstructured":"Allen HC, Sharma P. Histology, Plasma Cells. 2022."},{"key":"60729","doi-asserted-by":"crossref","unstructured":"Ijsselsteijn ME, van der Breggen R, Farina Sarasqueta A, Koning F, de Miranda NFCC. A 40-marker panel for high dimensional characterization of cancer immune microenvironments by imaging mass cytometry. Front Immunol. 2019; 10:2534.","DOI":"10.3389\/fimmu.2019.02534"},{"key":"60730","doi-asserted-by":"crossref","unstructured":"Le Rochais M, Hemon P, Pers JO, Uguen A. Application of high-throughput imaging mass cytometry hyperion in cancer research. Front Immunol. 2022; 13:859414.","DOI":"10.3389\/fimmu.2022.859414"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283344\/76175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283344\/76942","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11308\/76175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:06Z","timestamp":1794045906000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283344","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}